Abstract
There have been concerns about high rates of thus far undiagnosed SARS-CoV-2 infections in the health care system. The COVID-19 Contact (CoCo) Study follows 217 frontline healthcare professionals at a university hospital with weekly SARS-CoV-2 specific serology (IgA/IgG). Study participants estimated their personal likelihood of having had a SARS-CoV-2 infection with a mean of 20.9% (range 0 to 90%). In contrast, anti-SARS-CoV-2-IgG prevalence was about 1-2% at baseline. Regular anti-SARS-CoV-2 IgG testing of health-care professionals may aid in directing resources for protective measures and care of COVID-19 patients in the long run.
Competing Interest Statement
TW reports grants and personal fees from Novartis, grants and personal fees from Abbvie, personal fees from Gilead, personal fees from Chugai, personal fees from Sanofi-Aventis, non-financial support from Aesku.Diagnostics, outside the submitted work; AJ reports grants and personal fees from Novartis, grants and personal fees from Abbvie, grants and personal fees from Gilead, personal fees from Roche, outside the submitted work; Dr. Enst reports grants from Novartis, during the conduct of the study; grants and personal fees from Novartis, grants and personal fees from Abbvie, grants and personal fees from Gilead, personal fees from Sanofi Aventis, personal fees from GSK, outside the submitted work; No other competing interest are being declared.
Clinical Trial
DRKS00021152
Funding Statement
No external Funding for this work was received.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Individual deidentified participant data that underlie the results will be shared. The study protocol will be available 9 -36 months after publication with researchers who propose a methodically sound proposal, proposals should be directed to behrens.georg@mh-hannover.de
